Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions.

Kara I Cicero, Rahul Banerjee, Mary Kwok, Danai Dima, Andrew J Portuguese, Delphine Chen, Majid Chalian, Andrew J Cowan

Abstract readReview

In one paragraph

Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kara I CiceroClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-3030-3005

Rahul BanerjeeClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-3781-5441

Mary KwokClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Danai DimaClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

Andrew J PortugueseClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1010-4578

Delphine ChenDepartment of Radiology, University of Washington, Seattle, WA 98115, USA.

Majid ChalianDepartment of Radiology, University of Washington, Seattle, WA 98115, USA.ORCID 0000-0001-8400-1593

Andrew J CowanClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-1880-7094

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key goals for the management of myeloma precursor conditions include (1) identifying patients at the highest risk for progression to MM with bone involvement and (2) differentiating precursor states from active myeloma requiring treatment. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT with [

Indexed as

imagingMGUSmultiple myelomasmoldering multiple myeloma

Identifiers

PMID39857099

DOI10.3390/diagnostics15020215

PMCPMC11765077

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.